An interventional study of T3 with DCD tapered Prevail implant and Nanotite Certain tapered implant in Partial Edentulism and Tooth Disease, sponsored by ZimVie. Completed at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by ZimVie · Not applicable, Interventional, and Treatment
This study evaluates the T3 implant system for the preservation of alveolar crestal bone and the establishment of initial integration. The new surface-treated features of the implant may contribute to improved soft and hard tissue healing. The success rate of the T3 implant will be no different than that of the control implant, which possess similar geometry but different surface treatments.
This prospective, randomized-controlled study will enroll qualified patients with partial edentulism who will be treated with at least two dental implants. Implant sites will be randomly assigned to receive either a test (T3 implant) or control (Nanotite Certain Tapered implant) with an 80:20 (test:control) randomization ratio.
All implants will be allowed to integrate without occlusal forces and final restorations will be cemented thereafter.
Cumulative success rate and crestal bone regression of both treatment groups will be the primary and secondary study endpoints, respectively.
79 studies on the registry are indexed under Tooth Diseases; 11 are open to participants now.
This study's enrollment of 40 is below the median of 49 across 63 interventional studies indexed under Tooth Diseases.
Browse Tooth Diseases studies →ZimVie is the lead sponsor of 24 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
T3 with DCD tapered prevail implant
Device: T3 with DCD tapered Prevail implant
Nanotite Certain tapered implant
Device: Nanotite Certain tapered implant
T3 with DCD implant with Certain (internal) connection and platform-switch design
Also known as: T3 with Nanotite, T3 with platform switch
Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design
Also known as: Nanotite tapered certain, Non-platform switched
Cumulative Success Rate
Implant mobility is assessed by clinical evaluations and correlation to initial placement stability- insertion torque profiles.
Time frame: 1 year
Crestal Bone Changes
Crestal bone regression (amount of bone loss) between the two treatment groups will be compared
Time frame: 2 years
| Milestone | T3 With DCD Tapered Prevail Implant | Nanotite Certain Tapered Implant |
|---|---|---|
| Started | 32 | 8 |
| Completed | 27 | 3 |
| Not completed | 5 | 5 |
Implant mobility is assessed by clinical evaluations and correlation to initial placement stability- insertion torque profiles.
| implants | T3 With DCD Tapered Prevail Implant | Nanotite Certain Tapered Implant |
|---|---|---|
| Cumulative Success Rate | 61 | 7 |
Crestal bone regression (amount of bone loss) between the two treatment groups will be compared
| millimeters | T3 With DCD Tapered Prevail Implant | Nanotite Certain Tapered Implant |
|---|---|---|
| Crestal Bone Changes | 1.8 ± 0.9 | 3.3 ± 1.3 |
Collected over from enrollment until the end of 5 year follow up. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T3 With DCD Tapered Prevail Implant | 0/32 (0%) | 0/32 (0%) | 6/32 (18.8%) |
| Nanotite Certain Tapered Implant | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Event | T3 With DCD Tapered Prevail Implant | Nanotite Certain Tapered Implant |
|---|---|---|
| implant failureSurgical and medical procedures | 6/32 | 4/8 |
| Age, Categorical(Participants) | T3 With DCD Tapered Implant | Nanotite Certain Tapered Implant | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 22 | 5 | 27 |
| >=65 years | 10 | 3 | 13 |
| Sex: Female, Male(Participants) | T3 With DCD Tapered Implant | Nanotite Certain Tapered Implant | Total |
|---|---|---|---|
| Female | 17 | 5 | 22 |
| Male | 15 | 3 | 18 |
| Race and Ethnicity Not Collected(Participants) | T3 With DCD Tapered Implant | Nanotite Certain Tapered Implant | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.